General
Preferred name
MAPROTILINE
Synonyms
MAPROTILINE HYDROCHLORIDE ()
Ludiomil ()
CPD000148117 ()
Maprotiline HCl ()
Psymion ()
Deprilept ()
Maprotiline (hydrochloride) ()
BA-34,276 ()
NSC-757085 ()
BA-34276 HYDROCHLORIDE ()
BA-34276 ()
Maprotilina ()
BA-34,276 FREE BASE ()
BA-34,276 [AS HYDROCHLORIDE] ()
BA-34276 FREE BASE ()
Maprotiline-d3 (hydrochloride) ()
Maprotiline (hydrochloride) (CRM) ()
P&D ID
PD009633
CAS
10347-81-6
10262-69-8
1329496-63-0
Tags
available
drug
Approved by
FDA
First approval
1980
Drug indication
Anxiety
Major depressive disorder
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Maprotiline hydrochloride is a highly selective noradrenergic reuptake inhibitor that has strong antidepressant, antitumor and neuropathic pain-relieving effects with oral activity. Maprotiline hydrochloride induces cancer cell apoptosis by targeting the ERK signaling pathway and CRABP1[1][2].
PRICE 29
DESCRIPTION Maprotiline is a tetracyclic antidepressants (TeCA). (GtoPdb)
DESCRIPTION Selective norepinephrine reuptake inhibitor (LOPAC library)
DESCRIPTION Noradrenalin re-uptake inhibitor (Tocriscreen Total)
DESCRIPTION Maprotiline is a selective noradrenalin re-uptake inhibitor that binds the norepinephrine transporter. It is used to treat depressive illness, major depressive disorder, bipolar disorder, and anxiety associated with depression. (Enamine Bioactive Compounds)
DESCRIPTION Maprotiline hydrochloride (Psymion) is a bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
34
AdooQ Bioactive Compound Library
A10555
Bioprocess diversity set
Cayman Chemical Bioactives
15892
32702
33077
33301
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1237135
CHEMBL21731
ChEMBL Drugs
CHEMBL1237135
CHEMBL21731
Concise Guide to Pharmacology 2019/20
2402
Concise Guide to Pharmacology 2021/22
2402
Concise Guide to Pharmacology 2023/24
2402
CZ-OPENSCREEN Bioactive Library
DrugBank
DB00934
DrugBank Approved Drugs
DB00934
DrugCentral
1634
DrugCentral Approved Drugs
1634
DrugMAP
DMPWB7T
DrugMAP Approved Drugs
DMPWB7T
DrugMatrix
Enamine Bioactive Compounds
EBC-09124
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101781
Guide to Pharmacology
2402
Ki Database
MAPROTILINE
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL21731
MedChem Express Bioactive Compound Library
HY-B0444
NCATS Inxight Approved Drugs
2U1W68TROF
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Maprotiline-hydrochloride
TargetMol Bioactive Compound Library
T0172
The Spectrum Collection
Tocriscreen Total
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
277.18
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
4.21
TPSA
12.03
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Reuptake
Biological process
Mitosis & chromosome segregation
MOA
norepinephrine transporter inhibitor
Target
Norepinephrine transporter
Apoptosis
ERK
Adrenergic Receptor
5-HT
H1 receptor
mAChR
Noradrenaline transporter (Sodium-dependent)
Pathway
Autophagy
GPCR/G protein
Immunology/Inflammation
Neuroscience
MAPK/ERK Pathway
Stem Cell/Wnt
Therapeutic Class
Antidepressants
Source data